Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

MammoSite Radiation Therapy System distributor announced

MammoSite was developed by Proxima and cleared by the United States Food and Drug Administration (FDA) in May 2002 and received Australian Registration in June 2003. With this partnership, a 5-day treatment regimen of partial breast irradiation with MammoSite will now be available to more than 11,000 women diagnosed with breast cancer each year in Australia and New Zealand.

"The simplicity of the MammoSite therapy coupled with the short treatment time should be especially attractive to patients and...

• View Other Issues of Cancer Weekly
  
• View Other NewsRx Publications